Regulatory T cell therapy for Graft-versus-Host Disease.

IF 4.5 2区医学 Q1 HEMATOLOGY

Bone Marrow Transplantation Pub Date : 2025-04-16 DOI:10.1038/s41409-025-02553-x

Memnon Lysandrou, Dionysia Kefala, Janaki Manoja Vinnakota, Nikolaos Savvopoulos, Robert Zeiser, Alexandros Spyridonidis

引用次数: 0

Abstract

Graft-versus-Host Disease (GvHD) is the main cause of morbidity and mortality of allogeneic hematopoietic cell transplantation (allo-HCT). Conventional immunosuppressive pharmacotherapy remains the backbone of GvHD prevention and treatment with suboptimal outcomes especially for patients with refractory disease. Adoptive immunotherapy with regulatory T-cells (Treg) stands as an alternative approach that aims to restore immune tolerance and circumvent prolonged immunosuppression albeit preserving the beneficial Graft-versus-Leukaemia (GvL) effect. In this review, we summarise recent knowledge on Treg biology, clinical applications of various Tregs subtypes in the setting of GvHD and future endeavours of the field.

查看原文本刊更多论文

移植物抗宿主病的调节性T细胞治疗。

移植物抗宿主病（GvHD）是导致同种异体造血细胞移植（allo-HCT）发病和死亡的主要原因。传统的免疫抑制药物治疗仍然是GvHD预防和治疗的支柱，特别是对于难治性疾病的患者，结果不理想。调节性t细胞（Treg）的过继免疫治疗是一种替代方法，旨在恢复免疫耐受并避免长期免疫抑制，同时保留有益的移植物抗白血病（GvL）效应。在这篇综述中，我们总结了Treg生物学的最新知识，各种Treg亚型在GvHD中的临床应用以及该领域的未来努力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone Marrow Transplantation 医学-免疫学

CiteScore

8.40

自引率

8.30%

发文量

337

审稿时长

6 months

期刊介绍： Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation. The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.